Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 12

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 12
---
, Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application. Theranostic molecules are suitable for diagnosis and therapy of cancers. The PSMA ligand is a molecule that binds to the PSMA, an enzyme that is highly expressed in prostate cancer cells. The PSMA ligand is currently used for imaging and therapy to detect and treat prostate cancer.

| ● | Develop                                                                                           
 PSMA-B as a potential diagnostic and therapeutic molecule in pre-clinical models in collaboration 
 with academic nuclear medicine programs. Shuttle Pharma has licensed the intellectual property    
 for the prostate cancer predictive biomarker test from inventors and will seek additional         
 investment from NIH by applying for grant applications and from the public market to advance      
 pre-clinical development through its Shuttle Diagnostics entity.                                  |

| 5 |

Our Strategy

Our goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6 inhibitor (SP-2-225) and, if approved by the FDA, commercialize our product candidates for the treatment of cancers. While this process may require years to complete, we believe achieving this goal could result in new radiation sensitizer and immunotherapy products. Key elements of our strategy include:

| ● | Capitalize                                                                                                                                  
 on Ropidoxuridine as an orally available, small molecule radiation sensitizer. To date, there is one drug (Cetuximab, a monoclonal          
 antibody) approved by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine and obtaining       
 FDA approval, a small molecule sensitizer would then be enabled for clinical applications for radiation sensitization indications.          |
| ● | Expand                                                                                                                                      
 our leadership position within radiation sensitizers. In addition to our traditional radiation sensitizers, we plan to advance              
 our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation      
 therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma      
 to strive to develop an innovative and well-tolerated drug for proton therapy sensitization.                                                |
| ● | Execute                                                                                                                                     
 a disciplined business development strategy to strengthen our portfolio of product candidates. We have built our current product            
 pipeline through in-house discovery, development, partnerships with leading academic institutions and through in-licensing. We will         
 continue to evaluate new in-licensing